# 2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer

- Source: PR Newswire
- Published: 2026-10-25T06:00:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/2026-esmo--innovent-announcement-phase-2-data-presentation-for-ibi354-her2-adc-in-first-line-treatment-of-breast-cancer-302918639.html
- Canonical: https://groundlevelnews.com/story/2026-esmo-innovent-announcement-phase-2-data-presentation-for-ibi354-h-ab69ba/

SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune,...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire._